The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort
Open accessAbstract
Objective—: Ceramides are molecular lipids implicated in apoptosis, inflammation, obesity, and insulin resistance. An earlier study reported that ceramides were associated with fatal outcome among patients with coronary heart disease. Here, we examined whether ceramides are associated with major adverse cardiovascular events (MACEs) among apparently healthy individuals. Approach and Results—: FINRISK 2002 is a population-based risk factor survey, which recruited men and women aged 25 to 74 years. The cohort was followed up until the end of 2014. We quantified 4 circulating ceramides, Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), and Cer(d18:1/24:1), in 8101 serum samples by a targeted liquid chromatography–tandem mass spectrometry assay. Primary outcome of interest was incident MACE (n=813). Secondary analyses were performed for MACE death (n=116) without previous nonfatal MACE and for recurrent MACE (n=226) among survivors of a previous incident MACE. We used Cox proportional hazard models adjusted for the Framingham covariates to determine the association of ceramides with the outcomes. Of the ceramide species, Cer(d18:1/18:0) had the strongest association with incident MACE and the highest unadjusted hazard ratio of 1.31 (95% confidence interval, 1.21–1.41), which remained significant at 1.21 (95% confidence interval, 1.11–1.33) after Framingham risk factor adjustments. The hazard ratios were generally stronger for recurrent and fatal events than for first events. Clinical net reclassification improvement was 7.5% ( P =6.9×10 − 5 ) for Cer(d18:1/18:0). Conclusions—: Distinct serum ceramides are associated with the risk of incident MACE in apparently healthy individuals. These results should encourage more detailed analyses of ceramides in cardiovascular pathobiology and suggest new biomarkers of MACE risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sphingolipid metabolites in inflammatory disease
Maceyka, M., & Spiegel, S. (2014) · Nature · doi:10.1038/nature13475 · Cited by 1,277
Laaksonen, R., Ekroos, K., Sysi-Aho, M., Hilvo, M., Vihervaara, T., Kauhanen, D., Suoniemi, M., Hurme, R., März, W., Scharnagl, H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw148 · Cited by 674
Self-citationPredictive accuracy of the Framingham coronary risk score in British men:prospective cohort study
Brindle, P., Jonathan, E., Lampe, F., Walker, M., Whincup, P., Fahey, T., & Ebrahim, S. (2003) · BMJ · doi:10.1136/bmj.327.7426.1267 · Cited by 525
DeFilippis, A. P., Young, R., Carrubba, C. J., McEvoy, J. W., Budoff, M. J., Blumenthal, R. S., Kronmal, R. A., McClelland, R. L., Nasir, K., & Blaha, M. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1281 · Cited by 515
Hense, H. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00081-2 · Cited by 372
Plasma Lipidomic Analysis of Stable and Unstable Coronary Artery Disease
Meikle, P. J., Wong, G., Tsorotes, D., Barlow, C. K., Weir, J. M., Christopher, M. J., MacIntosh, G. L., Goudey, B., Stern, L., Kowalczyk, A., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.234096 · Cited by 306
Empana, J. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.09.002 · Cited by 263
Tarasov, K., Ekroos, K., Suoniemi, M., Kauhanen, D., Sylvänne, T., Hurme, R., Gouni-Berthold, I., Berthold, H. K., Kleber, M. E., Laaksonen, R., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2559 · Cited by 251
Self-citationCeramide synthases as potential targets for therapeutic intervention in human diseases
Park, J.-W., Park, W.-J., & Futerman, A. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.08.019 · Cited by 229
Prediction of first coronary events with the Framingham score: A systematic review
Eichler, K., Puhan, M. A., Steurer, J., & Bachmann, L. M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.02.027 · Cited by 214
Cited by
Sphingolipids and their metabolism in physiology and disease
Hannun, Y. A., & Obeid, L. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.107 · Cited by 2,051
Kim, Y.-R., Lee, E.-J., Shin, K.-O., Kim, M. H., Pewzner-Jung, Y., Lee, Y.-M., Park, J.-W., Futerman, A. H., & Park, W.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0340-1 · Cited by 474
Targeting a ceramide double bond improves insulin resistance and hepatic steatosis
Chaurasia, B., Tippetts, T. S., Mayoral Monibas, R., Liu, J., Li, Y., Wang, L., Wilkerson, J. L., Sweeney, C. R., Pereira, R. F., Sumida, D. H., et al. (2019) · Science · doi:10.1126/science.aav3722 · Cited by 450
Ceramides and other sphingolipids as drivers of cardiovascular disease
Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A., & Holland, W. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00536-1 · Cited by 387
Alterations in the gut microbiome and metabolism with coronary artery disease severity
Liu, H., Chen, X., Hu, X., Niu, H., Tian, R., Wang, H., Pang, H., Jiang, L., Qiu, B., Chen, X., et al. (2019) · Microbiome · doi:10.1186/s40168-019-0683-9 · Cited by 372
Metadata
- Authors
- Havulinna, A. S., Sysi-Aho, M., Hilvo, M., Kauhanen, D., Hurme, R., Ekroos, K., Salomaa, V., & Laaksonen, R.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-12
- Volume
- 36
- Issue
- 12
- Pages
- 2424-2430
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2537881633
- Cited by
- 343
- References
- 21
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. https://app.cochat.ai/papers/10.1161/atvbaha.116.307497
- The paper
- Havulinna, A. S., Sysi-Aho, M., Hilvo, M., Kauhanen, D., Hurme, R., Ekroos, K., Salomaa, V., & Laaksonen, R. (2016). Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.116.307497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.